Androstenedione

Androstenedione, or 4-androstenedione (abbreviated as A4 or Δ4-dione), also known as androst-4-ene-3,17-dione, is an endogenous weak androgen steroid hormone and intermediate in the biosynthesis of estrone and of testosterone from dehydroepiandrosterone (DHEA). It is closely related to androstenediol (androst-5-ene-3β,17β-diol).

This article is about androstenedione the hormone. For other uses, see Androstenedione (disambiguation).
Not to be confused with androstanedione or androstenediol.
Androstenedione
Clinical data
Other namesA4; Δ4-dione; Androstenedione; Androst-4-ene-3,17-dione; 4-Androstene-3,17-dione; 17-Ketotestosterone; 17-Oxotestosterone
Routes of
administration		By mouth
Drug classAndrogen; Anabolic steroid
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
MetabolismLiver
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.504
Chemical and physical data
FormulaC19H26O2
Molar mass286.415 g·mol−1
3D model (JSmol)
Melting point173–174[1] °C (343–345 °F)
  (verify)

Biological function

Androstenedione is a precursor of testosterone and other androgens, as well as of estrogens like estrone, in the body. In addition to functioning as an endogenous prohormone, androstenedione also has weak androgenic activity in its own right.

Androstenedione has been found to possess some estrogenic activity, similarly to other DHEA metabolites.[2] However, in contrast to androstenediol, its affinity for the estrogen receptors is very low, with less than 0.01% of the affinity of estradiol for both the ERα and ERβ.[3]

Adrenarche

In children aged 6 to 8 years old, there is a rise in androstenedione secretion along with DHEA during adrenarche. This rise in androstenedione and DHEA is hypothesized to play a crucial role for learning social, cultural and ecological skills, such as the development and understanding of sexual attraction. Furthermore, it is thought that androstenedione plays a role in levels of aggression and competition in boys, as a positive correlation between the two were observed, while testosterone levels were below detection.[4]

Biochemistry

Biosynthesis
Steroidogenesis. Androstenedione is at center.[5]

Androstenedione is the common precursor of the androgen and estrogen sex hormones.[6]

Androstenedione can be biosynthesized in one of two ways. The primary pathway involves conversion of 17α-hydroxypregnenolone to DHEA by way of 17,20-lyase, with subsequent conversion of DHEA to androstenedione via the enzyme 3β-hydroxysteroid dehydrogenase. The secondary pathway involves conversion of 17α-hydroxyprogesterone, most often a precursor to cortisol, to androstenedione directly by way of 17,20-lyase. Thus, 17,20-lyase is required for the synthesis of androstenedione, whether immediately or one step removed.

Androstenedione is produced in the adrenal glands and the gonads. The production of adrenal androstenedione is governed by adrenocorticotrophic hormone (ACTH), whereas production of gonadal androstenedione is under control by the gonadotropins. In premenopausal women, the adrenal glands and ovaries each produce about half of the total androstenedione (about 3 mg/day). After menopause, androstenedione production is about halved, due primarily to the reduction of the steroid secreted by the ovary. Nevertheless, androstenedione is the principal steroid produced by the postmenopausal ovary.

Some androstenedione is also secreted into the plasma, and may be converted in peripheral tissues to testosterone and estrogens.

Production rates, secretion rates, clearance rates, and blood levels of major sex hormones
Sex Sex hormone Reproductive
phase		 Blood
production rate		 Gonadal
secretion rate		 Metabolic
clearance rate		 Reference range (serum levels)
SI units Non-SI units
Men Androstenedione
–
 2.8 mg/day 1.6 mg/day 2200 L/day 2.8–7.3 nmol/L 80–210 ng/dL
Testosterone
–
 6.5 mg/day 6.2 mg/day 950 L/day 6.9–34.7 nmol/L 200–1000 ng/dL
Estrone
–
 150 μg/day 110 μg/day 2050 L/day 37–250 pmol/L 10–70 pg/mL
Estradiol
–
 60 μg/day 50 μg/day 1600 L/day <37–210 pmol/L 10–57 pg/mL
Estrone sulfate
–
 80 μg/day Insignificant 167 L/day 600–2500 pmol/L 200–900 pg/mL
Women Androstenedione
–
 3.2 mg/day 2.8 mg/day 2000 L/day 3.1–12.2 nmol/L 89–350 ng/dL
Testosterone
–
 190 μg/day 60 μg/day 500 L/day 0.7–2.8 nmol/L 20–81 ng/dL
Estrone Follicular phase 110 μg/day 80 μg/day 2200 L/day 110–400 pmol/L 30–110 pg/mL
Luteal phase 260 μg/day 150 μg/day 2200 L/day 310–660 pmol/L 80–180 pg/mL
Postmenopause 40 μg/day Insignificant 1610 L/day 22–230 pmol/L 6–60 pg/mL
Estradiol Follicular phase 90 μg/day 80 μg/day 1200 L/day <37–360 pmol/L 10–98 pg/mL
Luteal phase 250 μg/day 240 μg/day 1200 L/day 699–1250 pmol/L 190–341 pg/mL
Postmenopause 6 μg/day Insignificant 910 L/day <37–140 pmol/L 10–38 pg/mL
Estrone sulfate Follicular phase 100 μg/day Insignificant 146 L/day 700–3600 pmol/L 250–1300 pg/mL
Luteal phase 180 μg/day Insignificant 146 L/day 1100–7300 pmol/L 400–2600 pg/mL
Progesterone Follicular phase 2 mg/day 1.7 mg/day 2100 L/day 0.3–3 nmol/L 0.1–0.9 ng/mL
Luteal phase 25 mg/day 24 mg/day 2100 L/day 19–45 nmol/L 6–14 ng/mL
Notes and sources
Notes: "The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands, the rate of metabolism of precursor or prehormones into the steroid, and the rate at which it is extracted by tissues and metabolized. The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time. Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration. The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time. The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources, including secretion from glands and conversion of prohormones into the steroid of interest. At steady state, the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared (metabolic clearance rate) multiplied by blood concentration (production rate = metabolic clearance rate × concentration). If there is little contribution of prohormone metabolism to the circulating pool of steroid, then the production rate will approximate the secretion rate." Sources: See template.

Metabolism

Androstenedione is converted to either testosterone or estrone. Conversion of androstenedione to testosterone requires the enzyme 17β-hydroxysteroid dehydrogenase. Androstenedione is released into the blood by theca cells. Conversion of androstenedione to estrone requires the enzyme aromatase. Androstenedione is a substrate for estrogen production in granulosa cells which produce aromatase. Thus, theca cells and granulosa cells work together to form estrogens.[7]

Androstanedione is a 5α-reduced metabolite of 4-androstenedione which serves as an intermediate in the biosynthesis of the androgen and neurosteroid androsterone.[8]

Levels

Levels are normally 30–200 ng/dL (1.0–7.0 nmol/L) in females and 40–150 ng/dL (1.4–5.2 nmol/L) in males.[9]

Pharmacology

Androstenedione has been shown to increase serum testosterone levels over an eight-hour period in men when taken as a single oral dose of 300 mg per day, but a dose of 100 mg had no significant effect on serum testosterone.[10] However, serum levels of estradiol increased following both the 100 mg and 300 mg doses.[10] The study also reported that the serum level of estrogens and testosterone produced varied widely between individuals.[10]

A 2006 review paper summarized several studies that examined the effect of androstenedione on strength training.[11] At dosages of 50 mg or 100 mg per day, androstenedione had no effect on muscle strength or size, or on body fat levels.[11] One study used a daily dosage of 300 mg of androstenedione combined with several other supplements, and also found no increase in strength when compared to a control group that did not take the supplements.[11]

The review authors speculate that sufficiently high doses may indeed lead to increased muscle size and strength.[11] However, due to the federal ban on androstenedione supplements, it is difficult to carry out new research on its effects.[11] The review authors conclude that individuals should not use androstenedione supplements due to the lack of evidence of beneficial effects, the wide variation in individual responses to the supplement, and the risk of unknown side effects.[11]

Medical use

Under the brand name Metharmon-F and in combination with sex steroids (pregnenolone, testosterone, estrone, androstenediol) and thyroid hormone (desiccated thyroid), androstenedione is or has been marketed for medical use in Thailand.[12]

Chemistry
See also: List of androgens/anabolic steroids

Androstenedione, also known as androst-4-ene-3,17-dione, is a naturally occurring androstane steroid and a 17-ketosteroid. It is closely related structurally to androstenediol (A5; androst-5-ene-3β,17β-diol), dehydroepiandrosterone (DHEA; androst-5-en-3β-ol-17-one), and testosterone (androst-4-en-17β-ol-3-one), as well as to 5α-androstanedione (5α-androstane-3,17-dione) and estrone (estra-1,3,5(10)-triene-3-ol-17-one or 19-norandrost-1,3,5(10)-triene-3-ol-17-one).

History

Use as a supplement

Androstenedione was manufactured as a dietary supplement, often called andro or andros for short. Sports Illustrated credits Patrick Arnold with introducing androstenedione to the North American market.[13] Androstenedione was legal and able to be purchased over the counter, and, as a consequence, it was in common use in Major League Baseball throughout the 1990s by record-breaking sluggers like Mark McGwire.[14]

Barry R. McCaffrey, in his capacity as director of the White House Office of National Drug Control Policy, determined that androstenedione could not be classified as an anabolic steroid because there is no proof that it promotes muscle growth.[15]

Society and culture

Regulation

Androstenedione is banned by the World Anti-Doping Agency, and from the Olympic Games. The International Olympic Committee in 1997 banned androstenedione and placed it under the category of androgenic-anabolic steroids.[15] Androstenedione is banned by MLB, the NFL, USOC, NCAA, and by the NBA.[15]

On March 12, 2004, the Anabolic Steroid Control Act of 2004 was introduced into the United States Senate. It amended the Controlled Substance Act to place both anabolic steroids and prohormones on a list of controlled substances, making possession of the banned substances a federal crime. The law took effect on January 20, 2005. However, androstenedione was legally defined as an anabolic steroid, even though there is scant evidence that androstenedione itself is anabolic in nature. On April 11, 2004, the United States Food and Drug Administration banned the sale of androstenedione, citing that the drug poses significant health risks commonly associated with steroids. Androstenedione is currently banned by the U.S. military.[16]

gollark: Anyway, apparently, if we add several tens of solar masses of hydrogen to the sun, it will *not* become red.
gollark: In that case, just surround half the sun in a giant mirror.
gollark: Oh, you want to *move* it, not *destroy* it?
gollark: They lose mass too fast to become red supergiants and still retain high temperature.
gollark: Extremely large stars (>40 solar masses) apparently don't become red giants!

References
Citations
  1. "Androstenedione Compound Summary". PubChem. National Center for Biotechnology Information. U.S. National Library of Medicine.
  2. Miller KK, Al-Rayyan N, Ivanova MM, Mattingly KA, Ripp SL, Klinge CM, Prough RA (January 2013). "DHEA metabolites activate estrogen receptors alpha and beta". Steroids. 78 (1): 15–25. doi:10.1016/j.steroids.2012.10.002. PMC 3529809. PMID 23123738.
  3. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (March 1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.
  4. Gray PB, McHale TS, Carré JM (May 2017). "A review of human male field studies of hormones and behavioral reproductive effort". Hormones and Behavior. 91: 52–67. doi:10.1016/j.yhbeh.2016.07.004. PMID 27449532.
  5. Häggström M, Richfield D (2014). "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.005. ISSN 2002-4436.
  6. Devlin TM (2010). Textbook of Biochemistry: with Clinical Correlations (7th ed.). Hoboken, NJ: John Wiley & Sons. p. 432. ISBN 978-0-470-28173-4.
  7. Boulpaep EL, Boron WF (2005). Medical Physiology: A Cellular and Molecular Approach (Updated ed.). Philadelphia, Pa.: Elsevier Saunders. p. 1155. ISBN 978-1-4160-2328-9.
  8. Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M (2011). "Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders". Current Pharmaceutical Design. 17 (2): 151–67. doi:10.2174/138161211795049589. PMID 21361868.
  9. "Androstenedione, Serum". Test Catalog. Mayo Clinic. Retrieved 1 March 2014.
  10. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS (February 2000). "Oral androstenedione administration and serum testosterone concentrations in young men". JAMA. 283 (6): 779–82. doi:10.1001/jama.283.6.779. PMID 10683057.
  11. Brown GA, Vukovich M, King DS (August 2006). "Testosterone prohormone supplements". Medicine and Science in Sports and Exercise. 38 (8): 1451–61. doi:10.1249/01.mss.0000228928.69512.2e. PMID 16888459.
  12. https://www.medicinescomplete.com/mc/martindale/2009/20324-x.htm
  13. Dohrmann G (9 October 2006). "Is This Dr. Evil?". CNN. Archived from the original on 8 December 2012.
  14. https://www.cnbc.com/id/34822812
  15. Reents S (2000). Sport and Exercise Pharmacology. Champaign, Ill.: Human Kinetics. ISBN 978-0-87322-937-1.
  16. "'Andro' supplement off limits in new year". U.S. Air Force Medical Service. January 2005. Archived from the original on 10 February 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.